Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup
Research output: Contribution to journal › Journal article › Research › peer-review
Nonsteroidal antiandrogen monotherapy may be a treatment option for some patients with advanced prostate cancer. We report a survival and safety update from an analysis of 2 studies in which patients with nonmetastatic (M0) locally advanced disease were treated with either 150 mg. bicalutamide monotherapy or castration.
| Original language | English |
|---|---|
| Journal | Journal of Urology |
| Volume | 164 |
| Issue number | 5 |
| Pages (from-to) | 1579-82 |
| Number of pages | 4 |
| ISSN | 0022-5347 |
| Publication status | Published - 2000 |
ID: 48470867